Previous Close | 16.16 |
Open | 16.12 |
Bid | 16.10 x 900 |
Ask | 16.42 x 800 |
Day's Range | 15.83 - 16.48 |
52 Week Range | 10.23 - 24.00 |
Volume | 288,279 |
Avg. Volume | 213,473 |
Market Cap | 898M |
Beta (5Y Monthly) | 2.69 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -1.57 |
Earnings Date | Nov 7, 2019 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 14.67 |
Longtime CEO Lawrence Mehren has said he intends to retire at the end of January 2020 but will continue in a transitional part-time role for two years.
Accelerate Diagnostics, Inc. (NASDAQ: AXDX) announced today that Larry Mehren, chief executive officer, will participate in a 25-minute question and answer session at the 31st Annual Piper Jaffray Healthcare Conference in New York on December 4, 2019 at 3:30 p.m. Eastern Time. Jack Phillips, chief operating officer, and Steve Reichling, the company's chief financial officer, will accompany Mr. Mehren.
Accelerate Diagnostics, Inc. (NASDAQ:AXDX) today announced that Lawrence Mehren will retire from the company. Jack Phillips, the company's Chief Operating Officer, has been unanimously appointed by the board to the position, effective February 1, 2020. Mr. Mehren will support the transition process, remaining as a key advisor to the company through 2021. This move is the culmination of a succession plan initiated in 2018 by Mr. Mehren and the board to prepare the company for the next phase of commercial growth.
Larry Mehren has been the CEO of Accelerate Diagnostics, Inc. (NASDAQ:AXDX) since 2012. This report will, first...
Accelerate Diagnostics, Inc. (NASDAQ:AXDX) announced today that Louise Francesconi has been appointed to the company's Board of Directors.
Q3 2019 Accelerate Diagnostics Inc Earnings Call
Short interest can be an extremely helpful too for traders looking to get a feel for how a stock might react to a catalyst or gauge the overall bullish or bearish sentiment in a stock. Stocks with extremely ...
The companies on the 2019 Technology Fast 500 list are based on percentage fiscal year revenue growth from 2015 to 2018.
Accelerate Diagnostics (AXDX) delivered earnings and revenue surprises of 5.13% and -27.97%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
TUCSON, Ariz. , Nov. 7, 2019 /PRNewswire/ -- Accelerate Diagnostics, Inc. (Nasdaq: AXDX) today announced financial results for the third quarter ended September 30, 2019 . "Our placement and revenue ...
TUCSON, Ariz., Nov. 4, 2019 /PRNewswire/ -- Accelerate Diagnostics, Inc. (AXDX) today announced that Roland Diggelmann has been appointed to its Board of Directors. "On behalf of the entire board, I am delighted to welcome Roland to Accelerate Diagnostics," commented John Patience, Chairman of the Board of Directors. "Roland brings extensive experience from his decades of successful diagnostics company leadership.
Accelerate Diagnostics (AXDX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
The elite funds run by legendary investors such as David Tepper and Dan Loeb make hundreds of millions of dollars for themselves and their investors by spending enormous resources doing research on small cap stocks that big investment banks don't follow. Because of their pay structures, they have strong incentives to do the research necessary […]
TUCSON, Ariz. , Oct. 17, 2019 /PRNewswire/ -- Accelerate Diagnostics, Inc. (NASDAQ: AXDX) announced today that it will report financial results for the third quarter of 2019 after the market close on Thursday, ...
"We are thrilled to see these data, which demonstrate conclusively that the Accelerate PhenoTest™ BC kit positively impacts clinical outcomes across a diverse set of institutions and patient populations. The first of the studies is RAPIDS-GN (ClinicalTrials.gov # NCT03218397), a randomized controlled trial conducted at Mayo Clinic and UCLA. RAPIDS-GN focused on Gram-negative bacteremia and randomized patients to be tested by the BC kit or legacy methods. The study met the primary endpoint of therapy optimization, reporting time to first Gram-negative antibiotic change a full 24 hours sooner than legacy methods (17.4 hours vs. 42.1 hours, p
The idea of turning pocket change into a billion bucks is alluring. But this mirage of penny stocks is also nearly a complete fantasy.
Accelerate Diagnostics (AXDX) saw a big move last session, as its shares jumped more than 9% on the day, amid huge volumes.
TUCSON, Ariz., Sept. 18, 2019 /PRNewswire/ -- Accelerate Diagnostics, Inc. (AXDX) today announced the release of positive results from three clinical studies on the Accelerate Pheno™ system that will be presented at IDWeek™ 2019. The first of these studies is the ARLG-sponsored RAPIDS-GN clinical study conducted at Mayo Clinic and UCLA.
Q2 2019 Accelerate Diagnostics Inc Earnings Call
AXDX earnings call for the period ending June 30, 2019.
Accelerate Diagnostics (AXDX) delivered earnings and revenue surprises of 5.00% and -33.36%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
TUCSON, Ariz., Aug. 8, 2019 /PRNewswire/ -- Accelerate Diagnostics, Inc. (AXDX) today announced that Jack Phillips has been appointed Chief Operating Officer. Mr. Phillips joins Accelerate from Roche Diagnostics, the world's leading diagnostics company. Lawrence Mehren, President and Chief Executive Officer of Accelerate Diagnostics, commented, "We are thrilled to have an accomplished commercial leader of Jack's caliber join our team. This is an exciting time for Accelerate as we approach an inflection point in our commercial growth.
TUCSON, Ariz. , Aug. 8, 2019 /PRNewswire/ -- Accelerate Diagnostics, Inc. (Nasdaq: AXDX) today announced financial results for the second quarter ended June 30, 2019 . "We achieved mixed results in ...
It's easy to match the overall market return by buying an index fund. But if you buy individual stocks, you can do...
Accelerate Diagnostics (AXDX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.